# Hisky Medical Technologies Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hisky-medical-technologies-co

- Industry: Medical Devices & Equipment
- Headquarters: Wuxi, China
- Website: www.hiskymedical.com
- Total disclosed funding: $31M
- Latest round: Series D (Jan 10, 2025)
- Investors on record: 13

## About

Established in 2010, based in Beijing, China, Hisky Medical Technologies Co., Ltd is a medical device company that develops and manufactures non-invasive liver fibrosis diagnostic instruments. The company is originated from Tsinghua University. It has scientific research center, marketing center and technology transformation production center in Beijing, Shandong, and Jiangsu. Hisky has acquired more than 500 patents and China Patent Excellence Award. In January 2026, Hisky Medical Technologies Co., Ltd raised a venture funding from Jiuyu Investment.

Hisky offers products of liver diagnostic systems, its brands include iLivTouch and FibroTouch. The iLivTouch is a solution for liver fibrosis and hepatic steatosis diagnosis. The main prodcuts are non-invasive liver detection system, confocal microprobe imager, and ultrasound platform. The products provide image guidance, color ultrasound guidance, multi-channel guidance, smart portable, and cloud services. It has been used in screening, early prevention, diagnosis,treatment, and recovery of chronic liver disease.  

The company generates revenue by developing and providing liver testing equipment.

## Funding rounds

- Series D, Jan 10, 2025 — Riverhead Capital, Guangzhou Guoju Venture Capital, Hunan Hi-Tech Venture Capital Health $ Elderly Care Fund Management Co.,Ltd.
- Series B, Aug 14, 2021, $15M — Wuxi Huading Venture Capital, Zhongshan Investment Holding Group, Kunpeng Capital, Shenzhen Qianhai Beizeng Asset Management
- Series C, May 4, 2017 — TusStar
- Series B, Aug 4, 2016, $15M — Legend Capital, Chang'an Capital, 3E Bioventures Capital
- Series A, Jan 13, 2015 — Lotus Lake Capital, Shanghai China Healthcare Venture Management
- Series A, Mar 1, 2013, $0.8M — Lotus Lake Capital

## Investors

- Lotus Lake Capital (https://capitalatlas.ai/funds/lotus-lake-capital) — Series A
- Shanghai China Healthcare Venture Management (https://capitalatlas.ai/funds/shanghai-china-healthcare-venture-management) — Series A
- Legend Capital — Series B
- Chang'an Capital (https://capitalatlas.ai/funds/chang-an-capital) — Series B
- 3E Bioventures Capital (https://capitalatlas.ai/funds/3e-bioventures-capital) — Series B
- TusStar (https://capitalatlas.ai/funds/tusstar) — Series C
- Wuxi Huading Venture Capital (https://capitalatlas.ai/funds/wuxi-huading-venture-capital) — Series B
- Zhongshan Investment Holding Group — Series B
- Kunpeng Capital (https://capitalatlas.ai/funds/kunpeng-capital) — Series B
- Shenzhen Qianhai Beizeng Asset Management (https://capitalatlas.ai/funds/shenzhen-qianhai-beizeng-asset-management) — Series B
- Riverhead Capital (https://capitalatlas.ai/funds/riverhead-capital) — Series D
- Guangzhou Guoju Venture Capital (https://capitalatlas.ai/funds/guangzhou-guoju-venture-capital) — Series D
- Hunan Hi-Tech Venture Capital Health $ Elderly Care Fund Management Co.,Ltd. — Series D